425 related articles for article (PubMed ID: 23212609)
1. Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.
Dumont C; Mentré F; Gaynor C; Brendel K; Gesson C; Chenel M
Clin Pharmacokinet; 2013 Jan; 52(1):43-57. PubMed ID: 23212609
[TBL] [Abstract][Full Text] [Related]
2. PFIM 4.0, an extended R program for design evaluation and optimization in nonlinear mixed-effect models.
Dumont C; Lestini G; Le Nagard H; Mentré F; Comets E; Nguyen TT;
Comput Methods Programs Biomed; 2018 Mar; 156():217-229. PubMed ID: 29428073
[TBL] [Abstract][Full Text] [Related]
3. Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.
Thai HT; Mazuir F; Cartot-Cotton S; Veyrat-Follet C
Br J Clin Pharmacol; 2015 Sep; 80(3):534-47. PubMed ID: 26095234
[TBL] [Abstract][Full Text] [Related]
4. Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes.
Chenel M; Bouzom F; Aarons L; Ogungbenro K
J Pharmacokinet Pharmacodyn; 2008 Dec; 35(6):635-59. PubMed ID: 19130188
[TBL] [Abstract][Full Text] [Related]
5. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients.
Hennig S; Wainwright CE; Bell SC; Miller H; Friberg LE; Charles BG
Clin Pharmacokinet; 2006; 45(11):1099-114. PubMed ID: 17048974
[TBL] [Abstract][Full Text] [Related]
7. Optimization of individual and population designs using Splus.
Retout S; Mentré F
J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):417-43. PubMed ID: 15000423
[TBL] [Abstract][Full Text] [Related]
8. Development and evaluation of a generic physiologically based pharmacokinetic model for children.
Edginton AN; Schmitt W; Willmann S
Clin Pharmacokinet; 2006; 45(10):1013-34. PubMed ID: 16984214
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
10. Use of normalized prediction distribution errors for assessing population physiologically-based pharmacokinetic model adequacy.
Maharaj AR; Wu H; Hornik CP; Arrieta A; James L; Bhatt-Mehta V; Bradley J; Muller WJ; Al-Uzri A; Downes KJ; Cohen-Wolkowiez M
J Pharmacokinet Pharmacodyn; 2020 Jun; 47(3):199-218. PubMed ID: 32323049
[TBL] [Abstract][Full Text] [Related]
11. Does Sample Size, Sampling Strategy, or Handling of Concentrations Below the Lower Limit of Quantification Matter When Externally Evaluating Population Pharmacokinetic Models?
El Hassani M; Liebchen U; Marsot A
Eur J Drug Metab Pharmacokinet; 2024 Jul; 49(4):419-436. PubMed ID: 38705941
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis.
Peters SA
Clin Pharmacokinet; 2008; 47(4):261-75. PubMed ID: 18336055
[TBL] [Abstract][Full Text] [Related]
13. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4.
Bouillon-Pichault M; Jullien V; Bazzoli C; Pons G; Tod M
J Pharmacokinet Pharmacodyn; 2011 Feb; 38(1):25-40. PubMed ID: 21046208
[TBL] [Abstract][Full Text] [Related]
15. Influence of covariance between random effects in design for nonlinear mixed-effect models with an illustration in pediatric pharmacokinetics.
Dumont C; Chenel M; Mentré F
J Biopharm Stat; 2014; 24(3):471-92. PubMed ID: 24697342
[TBL] [Abstract][Full Text] [Related]
16. Optimal blood sampling time windows for parameter estimation using a population approach: design of a phase II clinical trial.
Chenel M; Ogungbenro K; Duval V; Laveille C; Jochemsen R; Aarons L
J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):737-56. PubMed ID: 16341474
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design.
Leroux S; Turner MA; Guellec CB; Hill H; van den Anker JN; Kearns GL; Jacqz-Aigrain E; Zhao W;
Clin Pharmacokinet; 2015 Dec; 54(12):1273-85. PubMed ID: 26063050
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetically based estimation of patient compliance with oral anticancer chemotherapies: in silico evaluation.
Hénin E; Tod M; Trillet-Lenoir V; Rioufol C; Tranchand B; Girard P
Clin Pharmacokinet; 2009; 48(6):359-69. PubMed ID: 19650675
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.
Zhao W; Cella M; Della Pasqua O; Burger D; Jacqz-Aigrain E;
Br J Clin Pharmacol; 2012 Apr; 73(4):641-50. PubMed ID: 21988586
[TBL] [Abstract][Full Text] [Related]
20. Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0.
Bazzoli C; Retout S; Mentré F
Comput Methods Programs Biomed; 2010 Apr; 98(1):55-65. PubMed ID: 19892427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
